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KEY POINTS
 Chronic kidney disease (CKD) is increasingly prevalent in patients with cardiovascular disease
(CVD), and the 2 disease processes are closely interlinked by both etiology and pathophysiology.
 Cardiac patients with CKD may present atypically and have a considerably worse prognosis in all
manifestations of CVD, as such, they warrant particularly vigilant specialist treatment.
 There is considerable evidence to support the use of most established cardiac interventions in pa-
tients with CKD, although many trials excluded patients with severe CKD and end-stage renal
failure.
 Close monitoring of CKD patients is necessary during the treatment of cardiovascular disease to
ensure safety and tolerability.
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81INTRODUCTION
Cardiovascular disease (CVD) and chronic kidney
disease (CKD) are both encompassing terms that
incorporate a spectrum of pathology that in the
case of CVD includes arterial atherosclerosis, heart
failure, diseases of the myocardium and pericar-
dium, valvular disease, and cardiac arrhythmias.
CKD in turn incorporates vascular, glomerular, tu-
bulointerstitial, and obstructive nephropathies
that result in a persistent (minimum of 3 months)
depression of glomerular filtration rate (GFR) lower
than 90 or, more typically, 60mL/min/1.73m2 (mild
and moderate CKD, respectively) and/or the pres-
ence of albuminuria. The severity of CKD is classi-
fied into 5 categories, as defined by the National
Kidney Foundation and the Kidney Disease
Outcome Quality Initiative (Table 1).1 Despite theThe authors have nothing to disclose.
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mdiversity of underlying abnormality in each patho-
logic condition, there appear to be several etiologic
factors shared between CVD and CKD. The non-
inheritable, noninfectious CVDs typically incorpo-
rate “traditional” cardiovascular risk factors that
include age, gender, hypertension, diabetes, dysli-
pidemia, smoking, and other lifestyle factors
including obesity. Given that the most common
forms of CKD share a significant number of these
risk factors, particularly hypertension and diabetes
(Fig. 1),2 it is unsurprising that a substantial propor-
tion of cardiac patients also have significant renal
impairment: approximately one-third of patients
presenting for coronary angiography will have
CKD3–5; in patients with heart failure the preva-
lence of CKD is estimated at between 32% and
53% (with the highest prevalence in those with
acute decompensation)6 and more than half ofst, 16-18Westmoreland Street, London,W1G8PH, UK;
London, 37 Chenies Mews, London, WC1E 6HX, UK
College Hospitals NHS Trust, 16-18 Westmoreland
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Table 1
Classification of chronic kidney disease according to estimated glomerular filtration rate (eGFR)
eGFR (mL/min/1.73 m2) Renal Dysfunction
5-Year Mortality
(All-Cause) (%)
Stage I >90 With urine/imaging abnormality —
Stage II 60–89 Mild 20
Stage IIIa 45–59 Moderate 24
Stage IIIb 34–44 Moderately severe 24
Stage IV 15–29 Severe 46
Stage V <15 End stage, requiring RRT 55
Mortality data derived from Keith et al,1 2004 and US Renal Data System 2013 Annual Data Report.108
Abbreviation: RRT, renal replacement therapy.
Rear et al2
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177patients with atrial fibrillation (AF) have CKD,7
increasing to nearly three-fourths of elderly AF pa-
tients (>80 years) considered for anticoagulant
therapy.8
By contrast, CVDs such as coronary artery dis-
ease and heart failure are highly prevalent in the
CKD population, and increasingly so with deterio-
rating renal function: in severe CKD (stage IV), the
prevalence of coronary artery disease (CAD) and
heart failure reaches 19.0% and 12.5%, respec-
tively.1 Within this same patient cohort, the preva-
lence of hypertension and diabetes in individuals
with CKD approaches 50% and 20%, respec-
tively. Significantly, these 2 comorbidities repre-
sent an increasing worldwide burden: in 2013, 1
billion people were treated for hypertension and
240 million patients for diabetes, with the totals
projected to increase to an estimated 1.56 billion
with hypertension by 2025 and 380 million with
diabetes over the next decade.2 In these groups,
the prevalence of CKD is 37% and 26%, respec-
tively, as reported by the US National Health and
Nutrition Examination Surveys.9 The prevalenceFig. 1. Significant overlap of risk factors of cardiovascula
shows the overlap between the conventional cardiovascula
kidney disease. Chemo, chemotherapeutic agents used in c
nary disease; NSAIDs, nonsteroidal anti-inflammatory drug
erythematosus.
ICCL137_proof ■ 4 Aprilof CKD is therefore anticipated to increase signifi-
cantly worldwide over the coming decades, and
although there have been significant improve-
ments in the rates of cardiovascular mortality
(particularly with deaths related to CAD, which
have fallen by approximately 50% over the last
3 decades10), globally the pressure exerted by
increasing prevalence of these comorbidities is
contrary to the continuation of this positive trend.
CVD and CKD are intricately linked, and their
prognoses interwoven. This review discusses
how CKD affects common CVD prognosis, and
the efficacy of and the adverse events arising
from clinical cardiovascular interventions.CORONARY ARTERY DISEASE
Atherosclerotic CAD is a prototypical example of
the interaction between CKD and CVD. Mild renal
dysfunction is increasingly recognized as a nontra-
ditional cardiovascular risk factor for CAD: modest
elevations of urinary albumin excretion below the
current microalbuminemia diagnostic thresholdr disease and chronic kidney disease. Venn diagram
r risk factors with the most common causes of chronic
ancer management; COPD, chronic obstructive pulmo-
s; PCKD, polycystic kidney disease; SLE, systemic lupus
2014 ■ 4:16 pm
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279are associated with elevated cardiovascular risk,11
which increases proportionately with progressive
renal deterioration.12 Moreover, CKD, once estab-
lished, doubles the rates of both CVD progres-
sion13 and in-hospital death following primary
percutaneous intervention (PCI) in comparison
with those without CKD.14 The accelerated pro-
gression of CVD in CKD is likely to be multifac-
torial, incorporating several nontraditional risk
factors that include hyperphosphatemia (and
vascular calcification),15 oxidative stress and
systemic inflammation,16 hyperhomocysteinemia,
hypervolemia, mineral/electrolyte imbalance, ane-
mia,17 thrombogenesis, and malnutrition. Conse-
quently, in the CKD patient cohort, CVD mortality
is not only 10 to 30 times higher than in the general
population,1 but CVD is a also more likely adverse
outcome than progressing to end-stage renal dis-
ease (ESRD) in these patients.18,19 Clinical man-
agement strategies therefore must center on the
management of the underlying kidney disease
and the common causes of hypertension and dia-
betes; there is emerging evidence that multidisci-
plinary approaches by nephrologists to control
the progression of renal disease pays dividends
in diminishing the rates of cardiovascular mortality
in these patients.20280
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309Difficulties in Diagnosis of Acute Coronary
Syndrome
The existence of CKD frequently presents sig-
nificant diagnostic challenges, not least in the
diagnosis of patients presenting with chest pain.
The electrocardiogram (ECG) frequently reveals
nonspecific abnormalities, so the diagnosis of
non–ST-elevation myocardial infarction, a more
frequent presentation than ST-elevation myocar-
dial infarction in CKD patients,21 requires further
supportive diagnostic evidence. Patients with
CKD frequently have elevated cardiac enzymes
on routine testing, which make interpretation of
absolute levels problematic, but a change of these
cardiac enzymes over a period of 3 to 6 hours will
be discriminatory for acute coronary syndrome
(ACS).22 However, persistently elevated cardiac
enzymes (such as troponin) should not be ignored
in CKD: their elevation is an independent risk fac-
tor for cardiovascular mortality.23 The cause of a
chronic troponin increase remains unclear, but is
likely to represent myocardial injury potentially
relating to microinfarction either secondary to
epicardial CAD (53% of patients with advanced
CKD will have a coronary stenosis of greater
than 50% in 1 or more coronary arteries24) or
attributable to microvascular dysfunction/left ven-
tricular hypertrophy, with data showing a strongICCL137_proof ■ 4correlation between left ventricular mass and
serum troponin levels.25
Conversely, the diagnosis of ACS may be
missed in patients with CAD and CKD, as the pre-
sentation is less likely to be with typical chest
pain,26 potentially reflecting an underlying neurop-
athy: in the SWEDEHEART register, 67% of CKD
patients with ACS had chest pain compared with
90% of those without CKD, and were more likely
to present with heart failure.21 Moreover, more
than half of patients referred for renal replacement
therapy (RRT) are found to have clinically signifi-
cant CAD in the absence of characteristic
ischemic symptoms.24
Noninvasive screening methods for CAD can be
used in patients with CKD. CKD patients are
vulnerable to calcification of the intima-media of
the coronary vessels. Cohort studies have demon-
strated CKD to be an independent predictor of
high computed tomography (CT) coronary artery
calcium (CAC) scores in patients with clinically
suspected CAD,27,28 and CAC scores correlate
with the stage of renal dysfunction.29 Despite
debate as to whether CT CAC scores correlate
with luminal narrowing, CAC scores are validated
as an independent predictor of future cardiac
events, correlating with cardiac mortality in CKD
patients.30,31 However, the nephrotoxic risk of
contrast exposure in CKD patients has meant
that there has been little study of CT–coronary
angiography in CKD. Of the other noninvasive
screening methods, single-photon emission CT
has variable and often low sensitivities in the
CKD cohort of patients, and although dobutamine
stress echo may be helpful in the screening of
CAD, interpretation can prove difficult in the pres-
ence of left ventricular hypertrophy frequently
found in CKD patients.32
Although the diagnosis of CAD in the CKD pa-
tient can be problematic, CKD patients have
such a high burden of CAD that any cardiovascular
presentation should be regarded with consider-
able suspicion and managed accordingly.26Medical Management of CAD in Patients with
CKD
Management of stable CAD consists of a combi-
nation of antiplatelet therapy, most commonly
with the cyclooxygenase inhibitor aspirin, and
aggressive traditional risk-factor management.
The coexistence of CKD does not significantly
alter this approach.
Aspirin remains beneficial in CKD patients with
CAD: in patients with diastolic hypertension, the
Hypertension Optimal Treatment (HOT) study
found a significant reduction of cardiovascularApril 2014 ■ 4:16 pm
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423events, particularly in those with more advanced
CKD (IIIb) managed with 75 mg aspirin, compared
with control (reduction of major cardiovascular
events by two-thirds, overall death reduced by
half), with a nonstatistically significant trend to-
ward higher bleeding rates (hazard ratio 2.81,
95% confidence interval [CI] 0.92–8.84, P 5 .3 in
the CKD-IIIb group).33,34
Reduction of traditional cardiovascular risk fac-
tors, particularly hypertension and dyslipidemia,
has the potential dual benefit of attenuating the
progression of both CVD and CKD. Management
of hypertension is well recognized and vital; cur-
rent guidelines provide a target blood pressure of
less than 140/90 mm Hg in the general population,
but is amended downward to 130/80 mm Hg in
those with CKD.35 The antihypertensive agents
targeting the renin-angiotensin-aldosterone axis,
specifically angiotensin-converting enzyme inhibi-
tors (ACE-Is) and angiotensin II receptor blockers
(ARBs), are discussed in greater detail in the rele-
vant section herein.
Some controversy has surrounded the effective-
ness of 3-hydroxy-3-methyl-glutaryl coenzyme A
reductase inhibitors (the statins) in the context of
CKD and CAD, but overall the data appear sup-
portive of lipid-lowering agents being helpful in
preventing the progression of cardiovascular, if
not necessarily renal disease, in both subgroup
analysis of existing cardiovascular trials4 and the
prospective Study of Heart and Renal Protection
(SHARP).36 Unfortunately, despite the evident
benefit of statin therapy in mild to moderate
CKD, statins are disappointingly ineffective in pre-
venting death from CVD in dialysis-dependent
end-stage CKD.37
b-Blockers for stable angina remain extremely
useful in the symptomatic relief of angina symp-
toms in patients with CKD, but dose adjustments
may need to be considered, particularly for the
more hydrophilic agents (atenolol, bisoprolol; see
later discussion).
In large part the medical management of CAD in
patients with CKD is largely unaltered, and the tar-
geting of cardiovascular risk factors benefits both
CVD and CKD, with the possible exception of
ESRD, in which the protective benefits of statin
therapy on CVD seem to be lost.
Implications of CKD and percutaneous coronary
intervention
Current interventional guidelines are clear in advo-
cating that ACSmanagement of patients with CKD
should not differ from that of patients without.38
However, it should be recognized that patients
with CKD have a worse short-term outcome and
a higher adverse event rate, particularly in regardICCL137_proof ■ 4 Aprilof major bleeding events, which are nearly double
that in the non-CKD population (multivariate odds
ratio 1.9, 95% CI 1.22–2.96).5,39 Great care needs
to be invested, therefore, to ensure the use of
appropriate doses of renal-excreted antithrom-
botic drugs, such as enoxaparin, fondaparinux, bi-
valirudin, and small-molecule glycoprotein IIb/IIIa
receptor blockers. In severe CKD these drugs
may be contraindicated, and unfractionated hepa-
rin used in their place.38
A similar pragmatic approach is used in the
management of stable CAD. In a post hoc analysis
of the Clinical Outcomes Utilizing Revasculariza-
tion and Aggressive Drug Evaluation (COURAGE)
trial comparing outcomes of patients with CKD
against those without, both patient groups had
similar benefits with identical management strate-
gies. Although PCI conferred no survival benefit in
patients with CKD,40 there was no adverse signal
with any combination of PCI and optimal medical
therapy, suggesting that these patients should be
managed in an individualized fashion comparable
with that for non-CKD patients.41
In themanagement of both ACS and stable CAD,
there needs to be cognizance of the problems
associated with contrast-induced acute kidney
injury (CI-AKI). Although CI-AKI is frequently a
short-term perturbation of creatinine clearance
and is self-limiting, nearly one-fifth of patients may
have persistent significant renal impairment3 and
up to 9%will progress to ESRD and dialysis.42 Cur-
rent guidelines recommend prehydration, cessa-
tion of nephrotoxic agents, and minimization of
contrast load,43 with much current research inter-
est in the potential beneficial roles of high-dose
statin44,45 and remote ischemic conditioning46,47
as renoprotective strategies during angiographic
procedures.
Implication of CKD and coronary artery bypass
surgery
Coronary artery bypass grafting (CABG) in patients
with CKD, as with PCI, is associated with higher
rates of adverse events, particularly for acute kid-
ney injury (25%–40% increase in CKD-III and
CKD-IV, respectively)48 and bleeding events.49
However, in comparison with PCI in patients with
complex, multivessel disease, CABG could be
considered as an alternative revascularization
strategy. In recent data from large cohort studies,
CABG has better cardiovascular outcomes, with
lower adjusted mortality, a lower rate of recurrent
ACS, and a lower requirement for revascularization
when compared with PCI.50,51 The presence of
CKD may also influence decisions regarding the
most appropriate surgical approach. In a cohort
study of patients undergoing CABG, the off-pump2014 ■ 4:16 pm
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500CABG (OPCAB) group had statistically lower rates
of in-hospital mortality and incident RRT in com-
parison with patients undergoing on-pump CABG
(ONCAB), with the strongest effect seen with
more advanced renal impairment: unadjusted in-
cidence of mortality in patients with a reduced
estimated GFR (eGFR; 15–29 and 30–59 mL/min/
1.73 m2) was lowest among the OPCAB (vs
ONCAB) cohort (3.5% vs 5.2% and 2.2% vs
2.4%, respectively), perhaps reflecting an injurious
effect of cardiopulmonary bypass and the potential
for transient organ hypoperfusion.52
Unfortunately there are no data available from
large-scale, multicenter, randomized controlled
trials to direct clinical management decisions
regarding revascularization in high-risk patients
with CKD, an area that would certainly benefit
from further focused study given the particular
problems presented by concomitant multivessel
CAD and CKD.501
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The Framingham Heart Study identified both val-
vular and nonvalvular risk factors for the develop-
ment of AF, with significant differences between
the genders: men had 50% greater AF prevalence
than women, and women were significantly more
likely than men to have a valvular etiology. It is
recognized that calcific valvular disease is itself
associated with CKD, particularly in dialysis-
requiring ESRD.53 Interestingly the major non-
valvular risk factors for the development of AF, in
addition to heart failure, are the traditional risk
factors for cardiovascular disease, namely age,
hypertension, and diabetes.54 Moreover, CKD is
associated with the development of left ventricular
hypertrophy, diastolic dysfunction, and subse-
quent left atrial dilatation,55 which increases the
likelihood of developing AF.56 Given the risk-
factor overlap between CKD and these recognized
risk factors for AF, it is not surprising to discover
that the prevalence of AF within the CKD cohort
of patients is high. In the Chronic Renal Insuffi-
ciency Cohort (CRIC) study, the prevalence of AF
is 2 to 3 times greater in patients with CKD
compared with the general population, with a prev-
alence of 16% with an eGFR 60 to 45 mL/min/
1.73 m2 rising to more than 20% when the eGFR
falls to less than 45 mL/min/1.73 m2,57 compared
with an estimate of 7.8% in the general population
in the REGARDS study.58 However, whether CKD
is a novel AF risk factor is unclear; the increased
prevalence of AF within this population may be
a simple expression of the presence of several
common cardiovascular/renovascular risk factors
(hypertension, aging, diabetes) leading to commonICCL137_proof ■ 4root disorders such as arterial atherosclerosis, dia-
stolic dysfunction, left ventricular hypertrophy, and
heart failure, but the metabolic and electrolyte ab-
normalities associated with more advanced CKD
may nonetheless be unique contributors toward
the increased prevalence of AF in the chronic renal
impairment cohort.59Impact of CKD on AF Management
In patients with persistent or permanent AF, in
whom rate control is the preferred strategy, the
use of drugs eliminated from the circulation by
the kidney present a particular problem, no
more so than for digoxin, which has a narrow ther-
apeutic index and is largely (90%) renally
excreted. Indeed, digoxin therapy is associated
with a 28% increased risk of death, associated
predominantly with toxic digoxin levels and the
presence of hypokalemia (a common electrolyte
imbalance before dialysis).60 Other rate-control
medications are also not entirely problem-free.
b-Blockers as a class have varied excretion: hy-
drophilic agents such as atenolol and sotolol
undergo renal elimination, and these drugs, like
those with mixed metabolism such as bisoprolol,
will require ECG monitoring and dose adjust-
ments; the best rate-control options in CKD may
therefore be lipophilic b-blockers such as meto-
prolol or carvedilol, or the use of a calcium-
channel blocker such as diltiazem.61 Similarly, in
pharmacologic rhythm control strategies, many
of the preferred therapy options are limited by
their dependence on renal excretion, including
sotolol and flecainide (reviewed in Ref.61). How-
ever, both dronedarone and amiodarone are
safe in patients with renal impairment.
Invasive interventions that can potentially cure
the arrhythmia are feasible in the context of CKD,
and the limitations to drug therapy imposed by
CKD seems to make this approach more attrac-
tive. However, it should be noted that the success
rate of AF ablation in the CKD population is some-
what lower than that found in the general popula-
tion, with AF recurrence rates after ablation
therapy typically 70% greater in CKD patients
than in the general population,62,63 with both low
eGFR and left atrial dilatation independently
adversely influencing the success of catheter abla-
tion.64 Therefore, the optimal approaches to the
management of AF in CKD patients require the
weighing of individual risk factors and outcome
benefits. However, as in other areas of CVD in
the context of CKD, the main problem in making
decisions regarding management of AF in CKD
patients is the lack of data from prospective ran-
domized controlled trials.April 2014 ■ 4:16 pm
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Although the inclusion of CKD as a risk factor does
not add to the power of the established predictive
systemic embolization CHADSVASc65 risk-scoring
system,66 CKD is nonetheless associated with a
significant increase in the risk of thromboembolic
stroke arising as a consequence of AF.67–69 Unfor-
tunately, CKD is also associated with increased
bleeding risk, and is recognized in scoring systems
such as the HAS-BLED score (Hypertension,
Abnormal liver/renal function, Stroke, Bleeding
history/predisposition, Labile anticoagulation re-
cord, Elderly [>65 years], Drugs/alcohol coadmin-
istration/use).70 Warfarin undergoes hepatic
metabolism using the cyp450 enzyme system,
although Limdi and colleagues71 found that
warfarin requirements were significantly lower in
patients with CKD than in the general population
(by 10% and 19% in moderate and severe CKD,
respectively). Strict monitoring of the international
normalized ratio in patients with CKD is therefore
mandatory, and CKD patients without close scru-
tiny of anticoagulation record suffer high bleeding
complication rates, particularly soon after initiation
of oral anticoagulant therapy.72
There is, however, a general lack of strong data
regarding the efficacy of warfarin and its ability to
attenuate the rate of thromboembolic stroke in
CKD patients, most data being retrospective and
nonrandomized.69,72–75 Moreover, warfarin is
associated with vascular calcification related to
vitamin K antagonism, and there are reported risks
of warfarin-related nephropathy.61 Despite this,
current guidance continues to support the use of
anticoagulation for thromboembolic risk reduction
in the CKD cohort, which until recently has meant
the administration and strict monitoring of
warfarin. However, the increasing availability of
novel oral anticoagulants will provide greater
choice in the management of thromboembolic
risk in patients with both AF and CKD. The anti-
thrombin dabigatran76 and the factor-Xa inhibitors
apixaban77 and rivaroxaban78 all show at leastTable 2
Prevalence of CKD by major CHF trial
Study Treatment Exclusion Crea
SOLVD109 Enalapril >177
CHARM110 Candesartan >265
CIBIS-II81 Bisoprolol >300
CARE-HF111 CRT N/A
Abbreviations: CHF, chronic heart failure; CKD, chronic kidney d
mated glomerular filtration rate; N/A, no data available.
ICCL137_proof ■ 4 Aprilnoninferiority to warfarin anticoagulation in pre-
venting thromboembolic stroke in mild andmoder-
ate CKD patients, with dabigatran and apixaban
showing superior systemic embolism risk reduc-
tion and dabigatran lower rates of intracranial
bleeding when compared with strictly monitored
warfarin therapy. Although all 3 of the novel oral
anticoagulants have at least an element of renal
elimination (dabigatran is 80% renally excreted;
the factor-Xa inhibitors less than one-third), all
can be used with dose modifications in patients
with mild and moderate CKD. None, however,
have been trialed in patients with severe CKD
and, consequently, only warfarin can be recom-
mended at present for use in patients with an
eGFR of less than 15 mL/min/1.73 m2.CHRONIC HEART FAILURE
Chronic heart failure (CHF) is a complex clinical
syndrome resulting from the inability of the heart
to maintain adequate tissue perfusion, because
of either structural or functional abnormalities
affecting the systolic and/or diastolic phase of
the cardiac cycle. CKD is highly prevalent in the
CHF patient cohort and, despite the usual exclu-
sion of patients with severe CKD, this is reflected
in the landmark heart failure trial literature, with
prevalence rates estimated between 32% and
50% (Table 2). CKD adversely affects the prog-
nosis of CHF: a recent meta-analysis of 85 CHF
trials (comprising 49,890 patients) revealed a
doubling of all-cause mortality within this patient
population (Table 3).6
The link between CHF and CKD is in part attrib-
utable to shared etiologic risk factors, but is also a
direct consequence of the interaction of their
respective pathophysiology (Fig. 2). For example,
low cardiac output and increased venous conges-
tion (predominant in heart failure with preserved
ejection fraction) respectively reduce renal arte-
rial blood flow and perfusion gradient,79 exacer-
bating kidney dysfunction, which can be furthertinine (mmol/L)
CKD Prevalence (%)
eGFR <60 mL/min/1.73 m2
32
36
33
50
isease; CRT, cardiac resynchronization therapy; eGFR, esti-
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All-cause mortality based on severity of CKDQ14
All CKD
32% Prevalence Moderate CKD Severe CKD
WRF
23% Prevalence
All-cause mortality 2.34 OR 1.59 HR 2.17 HR 1.81 OR
95% CI 2.2–2.5 95% CI 1.49–1.69 95% CI 1.95–2.40 95% CI 1.55–2.12
P<.001 P<.001 P<.001 P<.001
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio; OR, odds ratio; WRF, worsening
renal function.
Data from Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in
patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35(7):455–69.
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734aggravated by the therapies used to manage CHF,
through any combination of diuresis-associated
hypovolemia, renin-angiotensin-aldosterone sys-
tem (RAAS) inhibitors, and drug-induced hypo-
tension. By contrast, renal dysfunction leads to
neurohormonal dysregulation, anemia, volume
overload, and complex inflammatory cascades
that negatively affect cardiac function. The bidirec-
tional interaction between 2 failing organ systems
can lead to a vicious cycle of progressive cardiac
and renal dysfunction, termed cardiorenal syn-
drome, the classifications of which are summa-
rized in Table 4.80735
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750Medical Management of CHF in Patients with
CKD
The established canon of CHF management con-
sists of ACE-Is/ARBs, b-blockers, andmineralocor-
ticoid receptor antagonists (MRAs), with 2 decades
of landmarkmortality outcomedata to support their
use (Table 5). In patientswith normal renal function,
all improve prognosis, reduce hospitalizations, and
improve mortality rates. The coexistence of CKD,
however, introduces particular challenges for the
introduction and maintenance of CHF therapy.
Perhaps the most innocuous of these drug clas-
ses are the b-blockers. b-Blockers have no
adverse impact on the progression of CKD, andFig. 2. The cardiorenal syndrome: clinical features and p
central venous pressure; LV, left ventricle; RAAS, renin-an
ICCL137_proof ■ 4the efficacy of b-blockade in CHF seems unaltered
by the existence of CKD: a retrospective analysis
of outcomes in the CIBIS-II study reported pre-
served relative risk reduction in patients treated
with bisoprolol at all stages of CKD,81 data sup-
ported from observations in the MERIT-HF trial.82
As discussed earlier, individual b-blockers have
variable dependence on renal elimination: hydro-
philic drugs (atenolol and bisoprolol) will require
dose adjustments and monitoring in CKD,
whereas the lipophilic b-blockers (carvedilol and
metoprolol), which undergo hepatic metabolism,
do not,83 an observation that may help influence
the optimal choice of therapeutic agent.
By contrast, drugs that affect the RAAS axis
require greater caution when CHF coexists with
CKD. The ACE-Is/ARBs are a prototypical example
of this. In addition to their role in the management
of CHF, ACE-Is and ARBs are also pivotal to the
management of CKD, attenuating progression of
hypertensive, proteinuric CKD84 and lower mortal-
ity rates, as suggested by retrospective population
studies.85 However ACE-Is/ARBs are not innoc-
uous in terms of renal function: a modest perturba-
tion of GFR is frequently found following ACE-I or
ARB initiation, with an increase of creatinine to a
new 10- to 20-mmol/L higher baseline observed in
the CONSENSUS study.86 However, although
CHF studies excluded patients with severe CKD,athophysiologic mechanism. CO, cardiac output; CVP,
giotensin-aldosterone system.
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Table 4
Cardiorenal syndrome classification system adopted at the 2010 ADQI consensus conference
Type Inciting Event Secondary Disturbance Example
Type 1
Acute cardiorenal
syndrome
Abrupt worsening of
cardiac function
Acute kidney injury Acute cardiogenic
shock or acute
decompensation of
chronic heart failure
Type 2
Chronic cardiorenal
syndrome
Chronic abnormalities
in cardiac function
Chronic kidney damage Chronic heart failure
Type 3
Acute renocardiac
syndrome
Abrupt worsening of
renal function
Acute cardiac dysfunction
(eg, heart failure or
arrhythmia)
Acute kidney injury or
glomerular nephritis
Type 4
Chronic renocardiac
syndrome
Chronic kidney
disease
Decreased cardiac function,
cardiac hypertrophy,
and/or increased risk of
adverse cardiovascular
events
Chronic glomerular
disease
Type 5
Secondary cardiorenal
syndrome
Systemic disease Cardiac and renal
dysfunction
Diabetes mellitus,
systemic lupus,
sepsis, etc
Cardiorenal syndromes are divided into 5 categories according to triggering event and its consequence.
Abbreviation: ADQI, Acute Dialysis Quality Initiative.
Adapted from Ronco C, McCullough P, Anker SD, et al. Cardio-renal syndromes: report from the consensus conference
of the acute dialysis quality initiative. Eur Heart J 2010;31:703–11.
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878in patients withmild andmoderate CKD the cardio-
vascular mortality benefit of ACE-Is/ARBs appears
to be preserved.87–89
With respect to theMRAs, both the RALES90 and
EMPHASIS-HF studies91 (in which half and a third
of patients had CKD, respectively) demonstrated
mortality reductions (30% and 34%, respectively),
in addition to reduced symptoms and hospital-
izations. Both trials excluded patients with severe
CKD (RALES used a cutoff of 221 mmol/L;
EMPHASIS-HF an eGFR of 30 mL/min/1.73 m2),
but MRAs remain effective therapies in CHF when
there is coexistent mild to moderate CKD.92 Unfor-
tunately, the use of aldosterone antagonists in pa-
tients with severe CKD can provoke hyperkalemia,
especially in conjunction with ACE-Is or ARBs.
Current European guidelines recommend that a
serum creatinine level higher than 220 mmol/L or
potassium level higher than 5mmol/L is a contrain-
dication, although cautious use is usually well toler-
ated in mild or moderate CKD.93
Excessive sodium and water retention is usually
present in CHF patients with CKD, and should be
treated initially with dietary sodium restriction
(<2 g salt/d), but may require intensive diuretic
therapy using the minimum dose required to
achieve a “dryweight”; diuretic overdosing is asso-
ciated with increased mortality.94 Loop diuretics
are more effective than thiazide diuretics, and, ifICCL137_proof ■ 4 Aprilnecessary, cautious combination of both agents
may be used.95 However, unlike the MRA class of
diuretics, there is no prognostic benefit to be
derived from loop or thiazide diuretics in the setting
of either CHF or CKD.
Management of Anemia
Anemia is a significant problem in patients with
CHF and CKD, and often remains overlooked in
busy specialist clinics.96 CHF mortality increases
with severity of anemia by 50% to 100%97 and
the presence of CKD further doubles the mortal-
ity.98 Current European guidelines recommend
correcting hemoglobin levels to between 10 and
12 g/dL; however, recent systematic reviews and
meta-analyses have shown worse outcomes
when levels are normalized (>13 g/dL).99,100 Initial
correction of iron deficiency with oral or parenteral
iron before low-dose erythropoietin-stimulating
agents are recommended to minimize the need
for blood transfusions.
Device Therapy
Post hoc subanalysis of CARE-HF101 showed that
the relative effect of cardiac resynchronization
therapy (CRT) was similar among eGFR sub-
groups, whereas subanalysis of the MIRACLE
study demonstrated an improvement in baseline2014 ■ 4:16 pm
Table 5
Summary of the major CHF trials with CKD subgroup analysis data
Trial Name
Treatment/Target
(Mean Daily Dose) Outcome Effect (%)
CKD I–III
Effect CKD IV–V Effect
CONSENSUS112 Enalapril 20 mg bid
(18.4 mg)
1: All-cause
mortality
RRR 27,
ARR 15
Preserved Preserved (NS)
<30 mL/min/
1.73 m2
SOLVD109 Enalapril 10 mg bid
(16.6 mg)
1: All-cause
mortality
RRR 16 Preserved Preserved
<45 mL/min/
1.73 m2
CHARM-ALT110 Candesartan 32 mg
qd (23 mg)
1: CV mortality 1
HF admission
RRR 23, AR 7 Preserved No data
MERIT-HF113 Metoprolol 200 mg
qd (159 mg)
1: All-cause
mortality
RRR 34,
ARR 3.8
Preserved Preserved
<45 mL/min/
1.73 m2
CIBIS-II114 Bisoprolol 10 mg qd
(8.6 mg)
1: All-cause
mortality
RRR 32,
ARR 5.5
Preserved Preserved
<45 mL/min/
1.73 m2
COPERNICUS115 Carvedilol 25 mg
bid (37 mg)
1: All-cause
mortality
RRR 35,
ARR 5.6
Preserved Preserved
<45 mL/min/
1.73 m2
CAPRICORN116
RALES90 Spironolactone
50 mg qd (26 mg)
1: All-cause
mortality
RRR 30,
ARR 11
Preserved Contraindicated
EMPHASIS-HF91 Eplerenone 50 mg
qd (39.1 mg),
25 mg CKD III
1: CV mortality 1
HF admission
RRR 34,
ARR 7.6
Preserved Contraindicated
DIG117 Digoxin variable
(0.25 mg)
2: HF admission RRR 28,
ARR 7.9
Preserved Preserved
SHIFT118 Ivabradine 7.5 mg
bid (6.5 mg)
1: CV mortality1
HF admission
RRR 18,
ARR 5
No data No data
A-HEFT119 Hydralazine/ISDN
75 mg/40 mg tid
(142.5 mg/76 mg)
1: All-cause
mortalitya 1 HF
admissionb 1
QOL
RRR 43a/33bQ15 ,
ARR 4.0a/8b
No data No data
MADIT II120 ICD 1: All-cause
mortality
RRR 31,
ARR 5.6
Preserved Preserved (NS)
CARE-HF111 CRT 1: CV mortality 1
CV admission
RRR 37,
ARR 16
Preserved No data
MADIT-CRT121 CRT-D 1: All-cause
mortality 1 HF
admission
RRR 17.2,
ARR 8.1
Preserved No data
Abbreviations: ARR, absolute risk reduction; bid, twice daily; CRT, cardiac resynchronization therapy; CRT-D, cardiac re-
synchronization therapy with defibrillation; CV, cardiovascular; HF, heart failure; ICD, implantable cardioverter-
defibrillator; ISDN, isosorbide dinitrate; NS, not significant; qd, once daily; QOL, quality of life score; RRR, relative risk
reduction; tid, 3 times daily.
Kidney Disease in the Cardiac Patients 9
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991renal function.102 However, another subanalysis
of the REVERSE study103 found that CKD patients
treated with CRT had worse left ventricular param-
eter outcomes, which the investigators attributed
to CKD-specific impairment of reverse left ventric-
ular remodeling. For patients who might reason-
ably be expected to proceed to dialysis,
consideration of the site of arteriovenous fistula
before device implantation is recommended toICCL137_proof ■ 4avoid complications secondary to pacing wire–
associated central venous stenosis.104
Patients with CKD have a significantly increased
risk of sudden cardiac death (SCD) from ventricu-
lar arrhythmia, particularly so during dialysis, and
limited evidence suggests they should be offered
implantable cardioverter-defibrillator (ICD) therapy
if they meet the usual criteria105; however, con-
cerns exist regarding the efficacy of ICDs inApril 2014 ■ 4:16 pm
Rear et al10
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055ESRD.106 Unfortunately, SCD during dialysis may
occur in the absence of typical ICD criteria, owing
to complex interactions between hemodynamic,
electrolytic, hypertrophic, and electrophysiologic
factors,107 and further prospective studies are
required before any specific recommendations
can be made.9
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1089SUMMARY
Renal disease is a frequent partner of cardiovas-
cular disease, whereby the presence of one accel-
erates the progression of the other. Moreover,
renal disease adversely affects the efficacy and
tolerability of a range of medical, interventional,
and surgical interventions in CVD. Overall, how-
ever, the basic tenets of cardiovascular manage-
ment remain unchanged by the presence of renal
disease, no matter how advanced. Treatment pri-
orities remain the early identification of risk factors,
treatment and prevention of CKD and CVD where
possible, and, where present, attenuation of the
progression of both disease states. Moreover, cli-
nicians should avoid the occurrence of acute
kidney injury, through the use of drugs such as
ACE-Is, or the minimization of hypotension, neph-
rotoxics, or contrast agents during invasive or
surgical procedures. A key problem in the man-
agement of patients with CKD is the lack of pro-
spective, randomized controlled trials. Data from
such studies are sorely needed in a variety of areas
such as the optimum strategy in patients with
moderate and severe CKD and concomitant
CAD, CHF, or AF. Therefore, more extensive study
is required in this area of cardiovascular medicine
to broaden the understanding of the underlying
disease processes and to validate medical inter-
ventions from drugs through to surgery in the
context of kidney impairment, thus ensuring
optimal outcomes and preservation of quality of
life in this challenging patient cohort.10
11
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105REFERENCES
1. Keith DS, Nichols GA, Gullion CM, et al. Longitudi-
nal follow-up and outcomes among a population
with chronic kidney disease in a large managed
care organization. Arch Intern Med 2004;164:
659–63.
2. Bakris GL, Ritz E. The message for world kidney
day 2009: hypertension and kidney disease: a mar-
riage that should be prevented. Kidney Int 2009;
75:449–52.
3. Maioli M, Toso A, Leoncini M, et al. Persistent renal
damage after contrast-induced acute kidney injury:
incidence, evolution, risk factors, and prognosis.
Circulation 2012;125:3099–107.ICCL137_proof ■ 4 April4. Shepherd J, Kastelein JJ, Bittner V, et al. Intensive
lipid lowering with atorvastatin in patients with cor-
onary heart disease and chronic kidney disease:
the TNT (treating to new targets) study. J Am Coll
Cardiol 2008;51:1448–54.
5. Santopinto JJ, Fox KA, Goldberg RJ, et al. Creati-
nine clearance and adverse hospital outcomes in
patients with acute coronary syndromes: findings
from the global registry of acute coronary events
(grace). Heart 2003;89:1003–8.
6. Damman K, Valente MA, Voors AA, et al. Renal
impairment, worsening renal function, and
outcome in patients with heart failure: an updated
meta-analysis. Eur Heart J 2014;35:455–69.
7. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of
apixaban when compared with warfarin in relation
to renal function in patients with atrial fibrillation: in-
sights from the ARISTOTLE trial. Eur Heart J 2012;
33:2821–30.
8. Poli D, Antonucci E, Zanazzi M, et al. Impact of
glomerular filtration estimate on bleeding risk in
very old patients treated with vitamin k antagonists.
Results of EPICA study on the behalf of FCSA (Ital-
ian Federation of Anticoagulation Clinics). Thromb
Haemost 2012;107:1100–6.
9. Ostchega Y, Yoon SS, Hughes J, et al. Hyperten-
sion awareness, treatment, and control—continued
disparities in adults: United States, 2005-2006.
NCHS Data Brief 2008;1–8. Q
10. Nichols M, Townsend N, Scarborough P, et al.
Trends in age-specific coronary heart disease mor-
tality in the European Union over three decades:
1980-2009. Eur Heart J 2013;34:3017–27.
11. Cerasola G, Cottone S, Mule G. The progressive
pathway of microalbuminuria: from early marker
of renal damage to strong cardiovascular risk pre-
dictor. J Hypertens 2010;28:2357–69.
12. VanholderR,MassyZ,ArgilesA, et al. Chronic kidney
disease as cause of cardiovascular morbidity and
mortality. Nephrol Dial Transplant 2005;20:1048–56.
13. Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney
disease and cardiovascular disease in the Medi-
care population. Kidney Int Suppl 2003;S24–31. Q
14. Gevaert SA, De Bacquer D, Evrard P, et al. Renal
dysfunction in STEMI-patients undergoing primary
angioplasty: higher prevalence but equal prog-
nostic impact in female patients; an observational
cohort study from the Belgian STEMI Registry.
BMC Nephrol 2013;14:62.
15. Kanbay M, Goldsmith D, Akcay A, et al. Phos-
phate—the silent stealthy cardiorenal culprit in all
stages of chronic kidney disease: a systematic re-
view. Blood Purif 2009;27:220–30.
16. Cachofeiro V, Goicochea M, de Vinuesa SG, et al.
Oxidative stress and inflammation, a link between
chronic kidney disease and cardiovascular dis-
ease. Kidney Int Suppl 2008;S4–9. Q2014 ■ 4:16 pm
Kidney Disease in the Cardiac Patients 11
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
121917. McCullough PA, Lepor NE. Piecing together the ev-
idence on anemia: the link between chronic kidney
disease and cardiovascular disease. Rev Cardio-
vasc Med 2005;6(Suppl 3):S4–12.
18. Shulman NB, Ford CE, Hall WD, et al. Prognostic
value of serum creatinine and effect of treatment of
hypertension on renal function. Results from the hy-
pertension detection and follow-up program. The
Hypertension Detection and Follow-Up Program
Cooperative Group. Hypertension 1989;13:I80–93.
19. Berl T, Henrich W. Kidney-heart interactions: epide-
miology, pathogenesis, and treatment. Clin J Am
Soc Nephrol 2006;1:8–18.
20. Luciano Ede P, Luconi PS, Sesso RC, et al. Pro-
spective study of 2151 patients with chronic kidney
disease under conservative treatment with multi-
disciplinary care in the Vale do Paraiba, SP.
J Bras Nefrol 2012;34:226–34.
21. Szummer K, Lundman P, Jacobson SH, et al. Rela-
tion between renal function, presentation, use of
therapies and in-hospital complications in acute
coronary syndrome: data from the Swedeheart
Register. J Intern Med 2010;268:40–9.
22. Thygesen K, Alpert JS, Jaffe AS, et al. Third univer-
sal definition of myocardial infarction. J Am Coll
Cardiol 2012;60:1581–98.
23. End C, Seliger SL, Defilippi CR. Interpreting car-
diac troponin results from highly sensitive assays
in patients with chronic kidney disease: acute cor-
onary syndromes and beyond. Coron Artery Dis
2013;24:720–3.
24. Ohtake T, Kobayashi S, Moriya H, et al. High prev-
alence of occult coronary artery stenosis in pa-
tients with chronic kidney disease at the initiation
of renal replacement therapy: an angiographic ex-
amination. J Am Soc Nephrol 2005;16:1141–8.
25. Iliou MC, Fumeron C, Benoit MO, et al. Factors
associated with increased serum levels of cardiac
troponins Tand I in chronic haemodialysis patients:
Chronic Haemodialysis and New Cardiac Markers
Evaluation (CHANCE) study. Nephrol Dial Trans-
plant 2001;16:1452–8.
26. Komukai K, Ogawa T, Yagi H, et al. Renal insuffi-
ciency is related to painless myocardial infarction.
Circ J 2007;71:1366–9.
27. Kramer H, Toto R, Peshock R, et al. Association be-
tween chronic kidney disease and coronary artery
calcification: the Dallas Heart Study. J Am Soc
Nephrol 2005;16:507–13.
28. Cao XF, Yan LQ, Han LX, et al. Association of mild
to moderate kidney dysfunction with coronary ar-
tery calcification in patients with suspected coro-
nary artery disease. Cardiology 2011;120:211–6.
29. Budoff MJ, Rader DJ, Reilly MP, et al. Relationship
of estimated GFR and coronary artery calcification
in the CRIC (Chronic Renal Insufficiency Cohort)
study. Am J Kidney Dis 2011;58:519–26.ICCL137_proof ■ 430. Chiu YW, Adler SG, Budoff MJ, et al. Coronary ar-
tery calcification and mortality in diabetic patients
with proteinuria. Kidney Int 2010;77:1107–14.
31. Russo D, Morrone L, Russo L. Coronary artery
calcification and cardiovascular mortality in pre-
dialysis patients. Kidney Int 2011;79:258 [author
reply: 258].
32. Karthikeyan V, Ananthasubramaniam K. Coronary
risk assessment and management options in
chronic kidney disease patients prior to kidney
transplantation. Curr Cardiol Rev 2009;5:177–86.
33. Hansson L, Zanchetti A, Carruthers SG, et al. Ef-
fects of intensive blood-pressure lowering and
low-dose aspirin in patients with hypertension: prin-
cipal results of the Hypertension Optimal Treatment
(HOT) randomised trial. HOT Study Group. Lancet
1998;351:1755–62.
34. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin
is beneficial in hypertensive patients with chronic
kidney disease: a post-hoc subgroup analysis of
a randomized controlled trial. J Am Coll Cardiol
2010;56:956–65.
35. Rosendorff C. Hypertension and coronary artery
disease: a summary of the American Heart Associ-
ation scientific statement. J Clin Hypertens (Green-
wich) 2007;9:790–5.
36. Baigent C, Landray MJ, Reith C, et al. The effects
of lowering LDL cholesterol with simvastatin plus
ezetimibe in patients with chronic kidney disease
(Study of Heart and Renal Protection): a rando-
mised placebo-controlled trial. Lancet 2011;377:
2181–92.
37. Wanner C, Krane V, Marz W, et al. Atorvastatin in
patients with type 2 diabetes mellitus undergoing
hemodialysis. N Engl J Med 2005;353:238–48.
38. Hamm CW, Bassand JP, Agewall S, et al. ESC
guidelines for the management of acute coronary
syndromes in patients presenting without persis-
tent ST-segment elevation: the Task Force for the
Management of Acute Coronary Syndromes
(ACS) in patients presenting without persistent
ST-segment elevation of the European Society of
Cardiology (ESC). Eur Heart J 2011;32:2999–3054.
39. Moscucci M, Fox KA, Cannon CP, et al. Predictors
of major bleeding in acute coronary syndromes:
the Global Registry of Acute Coronary Events
(GRACE). Eur Heart J 2003;24:1815–23.
40. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Optimal
medical therapy with or without percutaneous cor-
onary intervention for patients with stable coronary
artery disease and chronic kidney disease. Am J
Cardiol 2009;104:1647–53.
41. Sedlis SP, Jurkovitz CT, Hartigan PM, et al. Health
status and quality of life in patients with stable cor-
onary artery disease and chronic kidney disease
treated with optimal medical therapy or percuta-
neous coronary intervention (post hoc findingsApril 2014 ■ 4:16 pm
Rear et al12
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333from the COURAGE trial). Am J Cardiol 2013;112:
1703–8.
42. Reed M, Meier P, Tamhane UU, et al. The relative
renal safety of iodixanol compared with low-
osmolar contrast media: a meta-analysis of ran-
domized controlled trials. JACC Cardiovasc Interv
2009;2:645–54.
43. Hecker PA, Leopold JA, Gupte SA, et al. Impact of
glucose-6-phosphate dehydrogenase deficiency
on the pathophysiology of cardiovascular disease.
AmJPhysiolHeart Circ Physiol 2013;304:H491–500.
44. Leoncini M, Toso A, Maioli M, et al. Early high-dose
rosuvastatin for contrast-induced nephropathy pre-
vention in acute coronary syndrome. Results from
Protective Effect of Rosuvastatin and Antiplatelet
Therapy on Contrast-Induced Acute Kidney Injury
and Myocardial Damage in Patients with Acute
Coronary Syndrome (PRATO-ACS study). J Am
Coll Cardiol 2013;63:71–9.
45. Hoshi T, Sato A, Kakefuda Y, et al. Preventive effect
of statin pretreatment on contrast-induced acute
kidney injury in patients undergoing coronary an-
gioplasty: propensity score analysis from a multi-
center registry. Int J Cardiol 2014;171:243–9.
46. Er F, Nia AM, Dopp H, et al. Ischemic precondition-
ing for prevention of contrast medium-induced ne-
phropathy: randomized pilot RENPRO trial (renal
protection trial). Circulation 2012;126:296–303.
47. Deftereos S, Giannopoulos G, Tzalamouras V, et al.
Renoprotective effect of remote ischemic post-
conditioning by intermittent balloon inflations in
patients undergoing percutaneous coronary inter-
vention. J Am Coll Cardiol 2013;61:1949–55.
48. Huang TM, Wu VC, Young GH, et al. Preoperative
proteinuria predicts adverse renal outcomes after
coronary artery bypass grafting. J Am Soc Nephrol
2011;22:156–63.
49. Winkelmayer WC, Levin R, Avorn J. Chronic kidney
disease as a risk factor for bleeding complications
after coronary artery bypass surgery. Am J Kidney
Dis 2003;41:84–9.
50. Chang TI, Leong TK, Kazi DS, et al. Comparative
effectiveness of coronary artery bypass grafting
and percutaneous coronary intervention for multi-
vessel coronary disease in a community-based
population with chronic kidney disease. Am Heart
J 2013;165:800–8, 808.e1–2.
51. Weintraub WS, Grau-Sepulveda MV, Weiss JM,
et al. Comparative effectiveness of revasculariza-
tion strategies. N Engl J Med 2012;366:1467–76.
52. Chawla LS, Zhao Y, Lough FC, et al. Off-pump
versus on-pump coronary artery bypass grafting
outcomes stratified by preoperative renal function.
J Am Soc Nephrol 2012;23:1389–97.
53. Umana E, Ahmed W, Alpert MA. Valvular and peri-
valvular abnormalities in end-stage renal disease.
Am J Med Sci 2003;325:237–42.ICCL137_proof ■ 4 April54. Benjamin EJ, Levy D, Vaziri SM, et al. Independent
risk factors for atrial fibrillation in a population-
based cohort. The Framingham Heart Study.
JAMA 1994;271:840–4.
55. Cerasola G, Nardi E, Palermo A, et al. Epidemi-
ology and pathophysiology of left ventricular abnor-
malities in chronic kidney disease: a review.
J Nephrol 2011;24:1–10.
56. Wachtell K, Devereux RB, Lyle PA, et al. The left
atrium, atrial fibrillation, and the risk of stroke in hy-
pertensive patients with left ventricular hypertro-
phy. Ther Adv Cardiovasc Dis 2008;2:507–13.
57. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kid-
ney disease and prevalent atrial fibrillation: the
Chronic Renal Insufficiency Cohort (CRIC). Am
Heart J 2010;159:1102–7.
58. Prineas RJ, Soliman EZ, Howard G, et al. The
sensitivity of the method used to detect atrial fibril-
lation in population studies affects group-specific
prevalence estimates: ethnic and regional distribu-
tion of atrial fibrillation in the regards study.
J Epidemiol 2009;19:177–81.
59. Korantzopoulos P, Liu T, Letsas KP, et al. The
epidemiology of atrial fibrillation in end-stage renal
disease. J Nephrol 2013;26:617–23.
60. Chan KE, Lazarus JM, Hakim RM. Digoxin associ-
ates with mortality in ESRD. J Am Soc Nephrol
2010;21:1550–9.
61. Nimmo C, Wright M, Goldsmith D. Management of
atrial fibrillation in chronic kidney disease: double
trouble. Am Heart J 2013;166:230–9.
62. Berkowitsch A, Kuniss M, Greiss H, et al. Impact of
impaired renal function and metabolic syndrome
on the recurrence of atrial fibrillation after catheter
ablation: a long term follow-up. Pacing Clin Electro-
physiol 2012;35:532–43.
63. Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant
chronic kidney disease increases the recurrence
of atrial fibrillation after catheter ablation of atrial
fibrillation: a mid-term follow-up. Heart Rhythm
2011;8:335–41.
64. Tokuda M, Yamane T, Matsuo S, et al. Relationship
between renal function and the risk of recurrent
atrial fibrillation following catheter ablation. Heart
2011;97:137–42.
65. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clin-
ical risk stratification for predicting stroke and
thromboembolism in atrial fibrillation using a novel
risk factor-based approach: the Euro Heart Survey
on Atrial Fibrillation. Chest 2010;137:263–72.
66. Roldan V, Marin F, Manzano-Fernandez S, et al.
Does chronic kidney disease improve the predic-
tive value of the CHADS2 and CHA2DS2-VASC
stroke stratification risk scores for atrial fibrillation?
Thromb Haemost 2013;109:956–60.
67. Go AS, Fang MC, Udaltsova N, et al. Impact of pro-
teinuria and glomerular filtration rate on risk of2014 ■ 4:16 pm
12
Kidney Disease in the Cardiac Patients 13
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447thromboembolism in atrial fibrillation: the Anticoa-
gulation and Risk Factors in Atrial Fibrillation
(ATRIA) study. Circulation 2009;119:1363–9.
68. Nakagawa K, Hirai T, Takashima S, et al. Chronic
kidney disease and CHADS(2) score indepen-
dently predict cardiovascular events and mortality
in patients with nonvalvular atrial fibrillation. Am J
Cardiol 2011;107:912–6.
69. Olesen JB, Lip GY, Kamper AL, et al. Stroke and
bleeding in atrial fibrillation with chronic kidney dis-
ease. N Engl J Med 2012;367:625–35.
70. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-
friendly score (has-bled) to assess 1-year risk of
major bleeding in patients with atrial fibrillation:
The Euro Heart Survey. Chest 2010;138:1093–100.
71. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin
dosing in patients with impaired kidney function.
Am J Kidney Dis 2010;56:823–31.
72. Chan KE, Lazarus JM, Thadhani R, et al. Warfarin
use associates with increased risk for stroke in he-
modialysis patients with atrial fibrillation. J Am Soc
Nephrol 2009;20:2223–33.
73. Winkelmayer WC, Liu J, Setoguchi S, et al. Effec-
tiveness and safety of warfarin initiation in older he-
modialysis patients with incident atrial fibrillation.
Clin J Am Soc Nephrol 2011;6:2662–8.
74. Lai HM, Aronow WS, Kalen P, et al. Incidence of
thromboembolic stroke and of major bleeding in
patients with atrial fibrillation and chronic kidney
disease treated with and without warfarin. Int J
Nephrol Renovasc Dis 2009;2:33–7.
75. Knoll F, Sturm G, Lamina C, et al. Coumarins and
survival in incident dialysis patients. Nephrol Dial
Transplant 2012;27:332–7.
76. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabiga-
tran versus warfarin in patients with atrial fibrilla-
tion. N Engl J Med 2009;361:1139–51.
77. Granger CB, Alexander JH, McMurray JJ, et al.
Apixaban versus warfarin in patients with atrial
fibrillation. N Engl J Med 2011;365:981–92.
78. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban
versus warfarin in nonvalvular atrial fibrillation.
N Engl J Med 2011;365:883–91.
79. Damman K, Navis G, Smilde TD, et al. Decreased
cardiac output, venous congestion and the associ-
ation with renal impairment in patients with cardiac
dysfunction. Eur J Heart Fail 2007;9:872–8.
80. Brown JR, Uber PA, Mehra MR. The progressive
cardiorenal syndrome in heart failure: Mechanisms
and therapeutic insights. Curr Treat Options Cardi-
ovasc Med 2008;10:342–8.
81. Erdmann E, Lechat P, Verkenne P, et al. Results
from post-hoc analyses of the CIBIS II trial: effect
of bisoprolol in high-risk patient groups with chronic
heart failure. Eur J Heart Fail 2001;3:469–79.
82. Ghali JK, Wikstrand J, Van Veldhuisen DJ, et al.
The influence of renal function on clinical outcomeICCL137_proof ■ 4and response to beta-blockade in systolic heart
failure: insights from Metoprolol CR/XL Random-
ized Intervention Trial in Chronic HF (MERIT-HF).
J Card Fail 2009;15:310–8.
83. Bakris GL, Hart P, Ritz E. Beta blockers in the man-
agement of chronic kidney disease. Kidney Int
2006;70:1905–13.
84. Sarafidis PA, Ruilope LM. Aggressive blood pres-
sure reduction and renin-angiotensin system
blockade in chronic kidney disease: time for re-
evaluation? Kidney Int 2013;85:536–46.
85. Molnar MZ, Kalantar-Zadeh K, Lott EH, et al. ACE
inhibitor and angiotensin receptor blocker use
and mortality in patients with chronic kidney dis-
ease. J Am Coll Cardiol 2013. Q
86. LjungmanS,KjekshusJ,SwedbergK.Renal function
in severe congestive heart failure during treatment
with enalapril (the Cooperative North Scandinavian
Enalapril Survival Study [Consensus] Trial). Am J
Cardiol 1992;70:479–87.
87. Swedberg K, Eneroth P, Kjekshus J, et al. Effects of
enalapril and neuroendocrine activation on prog-
nosis in severe congestive heart failure (follow-up
of the Consensus Trial). Consensus Trial Study
Group. Am J Cardiol 1990;66:40D–4D [discussion:
44D–45D].
88. Bowling CB, Sanders PW, Allman RM, et al. Effects
of enalapril in systolic heart failure patients with and
without chronic kidney disease: insights from the
SOLVD treatment trial. Int J Cardiol 2013;167:
151–6.
89. Konstam MA, Neaton JD, Dickstein K, et al. Effects
of high-dose versus low-dose losartan on clinical
outcomes in patients with heart failure (HEAAL
study): a randomised, double-blind trial. Lancet
2009;374:1840–8.
90. Pitt B, Zannad F, Remme WJ, et al. The effect of
spironolactone on morbidity and mortality in pa-
tients with severe heart failure. Randomized Aldac-
tone Evaluation Study Investigators. N Engl J Med
1999;341:709–17.
91. Zannad F, McMurray JJ, Krum H, et al. Eplerenone
in patients with systolic heart failure and mild
symptoms. N Engl J Med 2011;364:11–21.
92. Vardeny O, Wu DH, Desai A, et al, RALES Investi-
gators. Influence of baseline and worsening renal
function on efficacy of spironolactone in patients
with severe heart failure: insights from RALES (Ran-
domized Aldactone Evaluation Study). J Am Coll
Cardiol 2012;60:2082–9.
93. McMurray JJ, Adamopoulos S, Anker SD, et al,
Task Force for the Diagnosis and Treatment of
Acute and Chronic Heart Failure of the European
Society of Cardiology, Guidelines ESC Committee
for Practice. ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure 2012:
the Task Force for the Diagnosis and Treatment ofApril 2014 ■ 4:16 pm
13
Rear et al14
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571Acute and Chronic Heart Failure 2012 of the Euro-
pean Society of Cardiology. Developed in collabo-
ration with the Heart Failure Association (HFA) of
the ESC. Eur J Heart Fail 2012;14:803–69.
94. Eshaghian S, Horwich TB, Fonarow GC. Relation of
loop diuretic dose to mortality in advanced heart
failure. Am J Cardiol 2006;97:1759–64.
95. Wollam GL, Tarazi RC, Bravo EL, et al. Diuretic po-
tency of combined hydrochlorothiazide and furose-
mide therapy in patients with azotemia. Am J Med
1982;72:929–38.
96. TangWH, TongW, Jain A, et al. Evaluation and long-
term prognosis of new-onset, transient, and persis-
tent anemia in ambulatory patients with chronic
heart failure. J Am Coll Cardiol 2008;51:569–76.
97. Kosiborod M, Smith GL, Radford MJ, et al. The
prognostic importance of anemia in patients with
heart failure. Am J Med 2003;114:112–9.
98. Al-Ahmad A, Rand WM, Manjunath G, et al.
Reduced kidney function and anemia as risk fac-
tors for mortality in patients with left ventricular
dysfunction. J Am Coll Cardiol 2001;38:955–62.
99. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-
analysis: erythropoiesis-stimulating agents in pa-
tients with chronic kidney disease. Ann Intern
Med 2010;153:23–33.
100. Jing Z, Wei-jie Y, Nan Z, et al. Hemoglobin targets
for chronic kidney disease patients with anemia: a
systematic review and meta-analysis. PLoS One
2012;7:e43655.
101. Cleland JG, Daubert JC, Erdmann E, et al, Commit-
tee C-H study Steering Investigators. The CARE-HF
study (Cardiac Resynchronisation in Heart Failure
study): rationale, design and end-points. Eur JHeart
Fail 2001;3:481–9.
102. Boerrigter G, Costello-Boerrigter LC, Abraham WT,
et al. Cardiac resynchronization therapy improves
renal function in human heart failure with reduced
glomerular filtration rate. JCardFail 2008;14:539–46.
103. Bansal N, Tighiouart F, Weiner D, et al. Anemia as a
risk factor for kidney function decline in individuals
with heart failure. Am J Cardiol 2007;99:1137–42.
104. Spittell PC, Hayes DL. Venous complications after
insertion of a transvenous pacemaker. Mayo Clin
Proc 1992;67:258–65.
105. Herzog CA, Li S, Weinhandl ED, et al. Survival of
dialysis patients after cardiac arrest and the impact
of implantable cardioverter defibrillators. Kidney Int
2005;68:818–25.
106. Khan F, Adelstein E, Saba S. Implantable cardi-
overter defibrillators confer survival benefit in
patients with renal insufficiency but not in dialysis-
dependent patients. J Interv Card Electrophysiol
2010;28:117–23.
107. Green D, Roberts PR, New DI, et al. Sudden car-
diac death in hemodialysis patients: an in-depth re-
view. Am J Kidney Dis 2011;57:921–9.ICCL137_proof ■ 4 April108. U.S. Renal Data System. USRDS 2013 annual data
report: atlas of chronic kidney disease and end-
stage renaldisease in theUnitedStates. 2013. p. 1, 2. Q
109. Effect of enalapril on survival in patients with
reduced left ventricular ejection fractions and
congestive heart failure. The SOLVD investigators.
N Engl J Med 1991;325:293–302.
110. McMurray JJ, Ostergren J, Swedberg K, et al,
CHARM Investigators and Committees. Effects of
candesartan in patients with chronic heart failure
and reduced left-ventricular systolic function taking
angiotensin-converting-enzyme inhibitors: the
CHARM-added trial. Lancet 2003;362:767–71.
111. Cleland JG, Daubert JC, Erdmann E, et al. Cardiac
Resynchronization-Heart Failure Study I. The effect
of cardiac resynchronization on morbidity and
mortality in heart failure. N Engl J Med 2005;352:
1539–49.
112. Effects of enalapril on mortality in severe conges-
tive heart failure. Results of the Cooperative North
Scandinavian Enalapril Survival Study
(Consensus). The Consensus Trial Study Group.
N Engl J Med 1987;316:1429–35.
113. Effect of metoprolol CR/XL in chronic heart failure:
metoprolol CR/XL randomised intervention trial in
congestive heart failure (MERIT-HF). Lancet 1999;
353:2001–7.
114. The Cardiac Insufficiency Bisoprolol Study II
(CIBIS-II): a randomised trial. Lancet 1999;353:9–13.
115. PackerM,Coats AJ, FowlerMB, et al, Carvedilol Pro-
spective Randomized Cumulative Survival Study
Group. Effect of carvedilol on survival in severe
chronicheart failure.NEngl JMed2001;344:1651–8.
116. Dargie HJ. Effect of carvedilol on outcome after
myocardial infarction in patients with left-
ventricular dysfunction: the Capricorn randomised
trial. Lancet 2001;357:1385–90.
117. Digitalis Investigation Group. The effect of digoxin
on mortality and morbidity in patients with heart fail-
ure. N Engl J Med 1997;336:525–33.
118. Swedberg K, Komajda M, Bohm M, et al, SHIFT In-
vestigators. Ivabradine and outcomes in chronic
heart failure (SHIFT): a randomised placebo-
controlled study. Lancet 2010;376:875–85.
119. TaylorAL, ZiescheS, YancyC, et al, African-American
Heart Failure Trial Investigators. Combination of iso-
sorbide dinitrate and hydralazine in blacks with heart
failure. N Engl J Med 2004;351:2049–57.
120. Moss AJ, Zareba W, Hall WJ, et al, Multicenter
Automatic Defibrillator Implantation Trial II Investi-
gators. Prophylactic implantation of a defibrillator
in patients with myocardial infarction and reduced
ejection fraction. N Engl J Med 2002;346:877–83.
121. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-
resynchronization therapy for the prevention of
heart-failure events. N Engl J Med 2009;361:
1329–38.2014 ■ 4:16 pm
Our reference: ICCL 137 P-authorquery-v9
AUTHOR QUERY FORM
Journal: ICCL
Article Number: 137
Dear Author,
Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen
annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than
Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please
return your corrections within 48 hours.
For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.
Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in
the proof.
Location
in article
Query / Remark: Click on the Q link to find the query’s location in text
Please insert your reply or correction at the corresponding line in the proof
Q1 Please approve the short title to be used in the running head at the top of each right-hand page.
Q2 This is how your name will appear on the contributor’s list. Please add your academic title and any other
necessary titles and professional affiliations, verify the information, and OK
ROGER REAR, The Heart Hospital, University College Hospitals NHS Trust; The Hatter Cardiovascular
Institute, University College London, London, United Kingdom
PASCAL MEIER, The Heart Hospital, University College Hospitals NHS Trust, London, United
Kingdom
ROBERT M. BELL, The Heart Hospital, University College Hospitals NHS Trust; The Hatter
Cardiovascular Institute, University College London, London, United Kingdom
Q3 Are author names and order of authors OK as set?
Q4 Please provide professional degrees for all the authors.
Q5 The following synopsis is the one that you supplied, but edited down to fewer than 100 words. Please
confirm OK, or submit a replacement (also less than 100 words). Please note that the synopsis will appear in
PubMed: Traditional cardiovascular risk factors, particularly hypertension and diabetes, are common in the
disease processes of both renal and cardiac pathology. Unfortunately the coexistence of renal impairment is
not an innocent bystander in cardiovascular disease; the addition to cardiac disorder of involvement of
a second organ system not only increases the prevalence and severity of cardiovascular disease, it also
negatively affects prognostic outcomes and the safety and efficacy of cardiac interventions. This article
discusses the role and impact of kidney disease in the cardiac patient in 3 key common cardiovascular
processes: coronary artery disease, arrhythmia, and heart failure.
Q6 Please verify the affiliation addresses and provide the missing information (department name for both
affiliations). And please indicate (or confirm) which address is the preferred one for correspondence.
Q7 As per the editorial remarks, “Please check disclosure statement and change as necessary. Statement was
composed by Publisher.”
Q8 If there are any drug dosages in your article, please verify them and indicate that you have done so by
initialing this query.
Q9 Please provide the volume number.
Q10 Please provide the volume number.
Q11 Please provide the volume number.
Q12 Please provide the volume number and page range.
Q13 Please provide publisher name and location and also verify the page range.
Q14 As per the editorial remarks, “Please check the table caption and change as necessary. Caption was added
by publisher.”
Q15 The designators “a & b” are present in Table. Please specify in a footnote what they indicate.
Please check this box or indicate
your approval if you have no
corrections to make to the PDF file ,
Thank you for your assistance.
